Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?

Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?

Bibliographic Details
Main Authors: Varun Khetan, Erin A. Blake, Marcia A. Ciccone, Koji Matsuo
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Gynecologic Oncology Reports
Subjects:
Pembrolizumab
Rhabdomyolysis
Toxicity
Synchronous endometrial and vaginal cancer
Levonorgestrel intrauterine device
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578921000059
id doaj-9a2ecfe94a0a4661855b46c83198ef2b
record_format Article
spelling doaj-9a2ecfe94a0a4661855b46c83198ef2b2021-02-11T04:21:54ZengElsevierGynecologic Oncology Reports2352-57892021-02-0135100700Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?Varun Khetan0Erin A. Blake1Marcia A. Ciccone2Koji Matsuo3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USACorresponding author at: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue IRD 520, Los Angeles CA90033, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USAhttp://www.sciencedirect.com/science/article/pii/S2352578921000059PembrolizumabRhabdomyolysisToxicitySynchronous endometrial and vaginal cancerLevonorgestrel intrauterine device
collection DOAJ
language English
format Article
sources DOAJ
author Varun Khetan
Erin A. Blake
Marcia A. Ciccone
Koji Matsuo
spellingShingle Varun Khetan
Erin A. Blake
Marcia A. Ciccone
Koji Matsuo
Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
Gynecologic Oncology Reports
Pembrolizumab
Rhabdomyolysis
Toxicity
Synchronous endometrial and vaginal cancer
Levonorgestrel intrauterine device
author_facet Varun Khetan
Erin A. Blake
Marcia A. Ciccone
Koji Matsuo
author_sort Varun Khetan
title Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_short Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_full Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_fullStr Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_full_unstemmed Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_sort rhabdomyolysis following single administration of pembrolizumab: is severe immune-reaction a marker for durable treatment response?
publisher Elsevier
series Gynecologic Oncology Reports
issn 2352-5789
publishDate 2021-02-01
topic Pembrolizumab
Rhabdomyolysis
Toxicity
Synchronous endometrial and vaginal cancer
Levonorgestrel intrauterine device
url http://www.sciencedirect.com/science/article/pii/S2352578921000059
work_keys_str_mv AT varunkhetan rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
AT erinablake rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
AT marciaaciccone rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
AT kojimatsuo rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
_version_ 1724274621382918144

Similar Items